Social media hub

From complexity to clarity. See how ICON’s blended delivery model provides flexible, scalable solutions to suit or partners’ evolving clinical needs. Explore real results in our blended solutions case studies: https://o...

Preparing clinical data for submission to both the FDA and PMDA can be demanding. But with shared expectations and overlapping standards, there is a clear opportunity to streamline the process. Our latest whitepaper offe...

Susie McEvoy's path at ICON illustrates what it means to grow with purpose. Since joining as an HR Project Analyst in 2013, Susie has pursued every opportunity - from pioneering new roles to seeking mentorship, ultimatel...

2025 survey insights reveal developers are divided on the best launch strategy for multi-indication therapies. Approximately 31% prefer launching in a broad population, while 27% favor starting with a narrower indication...

August is Psoriasis Awareness Month, honoring the 8+ million people in the U.S. living with this chronic condition. Behind every new treatment is a journey to understand what patients need, and what keeps them from stay...

For #NationalImmunisationAwarenessMonth our blog looks at the recent history and the future of vaccines. Vaccine developers have an active role to play in supporting individuals and physicians to make informed decisions ...

If you would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter. https://ow.ly/jY7C50WwH5E Compiled and collated by ICON’s Regulatory Intelligence Team and de...

Multi-indication development strategies help increase a drug candidate's overall value, but remain complex and increasingly expensive, requiring significant clinical, administrative and site monitoring costs. Learn how d...

Delphi panels are a powerful way to gather expert consensus and patient insights—but designing them isn’t always straightforward. ICON’s experts explain how to tailor Delphi panel designs to meet your research goals. Le...

Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse a...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

Join ICON at the #SCDM 2025 South Africa Single Day Event on 22 August in Bloemfontein. Madelie Gerber will present on regulatory updates, offering perspectives on their impact on data management, while Marike Brandt wil...